PMV Pharmaceuticals to Participate at Upcoming Investor Conferences
PMV Pharmaceuticals (Nasdaq: PMVP), a precision oncology company focused on p53-targeting therapies, has announced its participation in two major upcoming investor conferences.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
PMV Pharmaceuticals (Nasdaq: PMVP), a precision oncology company focused on p53-targeting therapies, has announced its participation in two major upcoming investor conferences. David H. Mack, Ph.D., President and CEO, and Deepika Jalota, Pharm. D., Chief Development Officer, will represent the company.
The conferences include the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 12, 2025, at 12:40 PM EST, and the TD Cowen 45th Annual Health Care Conference on March 4, 2025, at 3:10 PM EST. Management will also conduct one-on-one investor meetings during these events.
Live audio webcasts will be available online, with archived replays accessible for 90 days following each presentation through the company's Events & Presentations platform.
Details
News Market Reaction – PMVP
The recorded move for PMVP in the trading session of this news was -2.10%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
PRINCETON, N.J., Feb. 11, 2025 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today announced that David H. Mack, Ph.D., President and Chief Executive Officer and Deepika Jalota, Pharm. D., Chief Development Officer, will participate at the following investor conferences. Management will also participate in one-on-one investor meetings.
Oppenheimer 35th Annual Healthcare Life Sciences Conference
Date: Wednesday, February 12, 2025
Time: 12:40 PM EST
TD Cowen 45th Annual Health Care Conference
Date: Tuesday, March 4, 2025
Time: 3:10 PM EST
A live audio webcast of the events will be available online at Events & Presentations. An archived replay of the events will be available for 90 days following the webcast at Events & Presentations.
About PMV Pharma
PMV Pharma is a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53. TP53 mutations are found in approximately half of all cancers. Our co-founder, Dr. Arnold Levine, established the field of p53 biology when he discovered the p53 protein in 1979. Bringing together leaders in the field to utilize more than four decades of p53 biology, PMV Pharma combines unique biological understanding with a pharmaceutical development focus. PMV Pharma is headquartered in Princeton, New Jersey. For more information, please visit www.pmvpharma.com.
Investors Contact:
Tim Smith
Senior Vice President, Head of Corporate Development and Investor Relations
investors@pmvpharma.com
Media Contact:
Kathy Vincent
Greig Communications
kathy@greigcommunications.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.